Pimecrolimus (hydrate)

Pimecrolimus hydrate (SDZ-ASM 981 hydrate) is a potent, nonsteroid and orally active calcineurin inhibitor. Pimecrolimus hydrate shows anti-inflammatory activity. Pimecrolimus hydrate has the potential for the research of atopic dermatitis and oral erosive lichen planus[1][2][3].

Product Specifications

CAS Number

[1000802-56-1]

Product Name Alternative

SDZ-ASM 981 (hydrate)

UNSPSC

12352211

Target

Phosphatase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pimecrolimus-hydrate.html

Purity

98.0

Solubility

10 mM in DMSO

Smiles

O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@@H](Cl)CC4)[C@H](C)[C@@H](O)CC3=O.[x].O

Molecular Formula

C43H68ClNO11.xH2O

References & Citations

[1]Grassberger M, et al. Pimecrolimus -- an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004 Dec;13 (12) :721-30.|[2]Roman D, et al. Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation. Toxicol Lett. 2004 Apr 1;149 (1-3) :133-40.|[3]Passeron T, et al. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol. 2007 Apr;143 (4) :472-6.